CTOs on the Move

Rehab 2 Perform

www.rehab2perform.com

 
R2P creates a unique physical therapy experience, offering our blend of performance, return to sport, physical therapy, dry needling and injury prevention.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ETHEX

ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Columbus Prescription Pharmacies

Columbus Prescription Pharmacies, Inc. is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rondo-Pak

Rondo-Pak is a global print and packaging specialist providing effective solutions and comprehensive services to the pharmaceutical and life sciences industries. The company`s portfolio of sophisticated packaging solutions addresses precise requirements for compliance, child resistance, anti-counterfeiting e-pedigree and more. Rondo-Pak has been a recognized leader in pharmaceutical folding cartons for over 70 years, and is a proud part of the Körber Medipak network of companies.